Search Results

You are looking at 51 - 60 of 654 items for :

  • "immunotherapy" x
  • Refine by Access: All x
Clear All
Full access

T-Cell Subsets as Potential Biomarkers for Hepatobiliary Cancers and Selection of Immunotherapy Regimens as a Treatment Strategy

Chandan Kumar-Sinha and Vaibhav Sahai

immune microenvironment and systemic immune factors that together determine the response to immunotherapy. 25 This review presents a brief overview of recent literature highlighting the tumor microenvironment (TME) immune milieu in HBTCs, with specific

Full access

Pancreatic Cancer Progression in a Patient With Lynch Syndrome Receiving Immunotherapy: A Cautionary Tale

Yifan Wang, Adeline Cuggia, Alain Pacis, Jean-Christian Boileau, Victoria A. Marcus, Zu-Hua Gao, George Chong, William D. Foulkes, and George Zogopoulos

pembrolizumab, restaging tomographic scans showed rapid progression of the liver metastases present at the start of immunotherapy. There was a >2-fold increase in the rate of tumor growth on pembrolizumab compared with that on gemcitabine/nab-paclitaxel, meeting

Full access

Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of Novel Therapies: A Guideline Appraisal

Ronald Chow, Daniel E. Lage, Grant R. Williams, Mina S. Sedrak, Joseph A. Greer, Jennifer S. Temel, and Ryan D. Nipp

trials in the era of targeted therapy and immunotherapy. In the current study, we sought to analyze the representation and outcomes of older adults in pivotal clinical trials in the first-line metastatic setting for the 5 leading causes of cancer death

Full access

Defining and Managing High-Risk Multiple Myeloma: Current Concepts

Luciano J. Costa and Saad Z. Usmani

superfamily involved in the regulation of B-cell proliferation and survival and maturation/differentiation into PCs, making it an attractive target for immunotherapy. 45 CAR T cells are autologous T cells collected via apheresis and engineered to express the

Full access

Immunotherapy for Lung Cancer: Many Questions Yet to Be Answered

David S. Ettinger

has been made in the systemic therapy for advanced NSCLC. However, the latest advance and most hopeful therapy for patients with lung cancer is immunotherapy. With immunotherapy, we can say, “the future is now!” We can look at a number of milestones

Full access

BIO22-026: Chemotherapy and Immunotherapy Infusion Reaction Documentation Standardization

Leah Anton, Lauren Gallegos, and Chaitra Swain Simpson

Background : Chemotherapy and immunotherapy infusion reactions are common medical emergencies that occur in ambulatory infusion centers. It is common practice for institutions to have clinical hypersensitivity and infusion reaction protocols

Full access

A Multidisciplinary Toxicity Team for Cancer Immunotherapy–Related Adverse Events

Jarushka Naidoo, Jiajia Zhang, Evan J. Lipson, Patrick M. Forde, Karthik Suresh, Kendall F. Moseley, Seema Mehta, Shawn G. Kwatra, Alyssa M. Parian, Amy K. Kim, John C. Probasco, Rosanne Rouf, Jennifer E. Thorne, Satish Shanbhag, Joanne Riemer, Ami A. Shah, Drew M. Pardoll, Clifton O. Bingham III, Julie R. Brahmer, and Laura C. Cappelli

diagnosis and positively influence management across tumor types. 1 – 5 More recently, specialized molecular tumor boards that interpret patient genomic data to guide clinical care have gained popularity. 6 In the field of cancer immunotherapy, emerging

Full access

NCCN Guidelines® Updates: Management of Immunotherapy-Related Toxicities

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Management of Immunotherapy-Related Toxicities, published in this issue (page 387), include the latest updates. To assist readers interested in noting how the guidelines were

Full access

Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials

Antonious Hazim, Gordon Mills, Vinay Prasad, Alyson Haslam, and Emerson Y. Chen

shown to occur most often at the recommended phase II dose (RP2D), or at approximately 81% to 120% of RP2D. 1 Recent advances in drug development have allowed for targeted agents, immunotherapy, and other classes of agents, which, in regard to efficacy

Full access

Personalizing Precision Oncology: From Light Microscope to Molecular Microscope

Vivek Subbiah and Kanishka Sircar

fueled by clinical next-generation sequencing (NGS) has come an exponential growth in the use of genomically targeted therapy and immunotherapy. NGS is most commonly used in advanced, metastatic cancer and in rare cancers in which conventional histologic